ADmit Therapeutics, a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), is dedicated to the development and commercialization of a cutting-edge Alzheimer's disease (AD) early detection technology. With a focus on rigurous analysis, efficiency, and agility, ADmit Therapeutics offers a diagnostic test that identifies biomarkers unrelated to β-amyloid or tau proteins. These biomarkers can be instrumental in detecting AD in its early stages, allowing for timely intervention and improved patient outcomes.

In recent news, ADmit Therapeutics has secured a significant investment of up to $1,886,058 from the Diagnostics Accelerator, a program by the Alzheimer's Drug Discovery Foundation. This investment supports the clinical validation and regulatory approval of ADmit Therapeutics' breakthrough technology utilizing novel biomarkers associated with mitochondrial DNA. Led by a team of experts, including CEO Marta Barrachina and medical advisory board members Ramón Reñé and Jordi Gascón, ADmit Therapeutics is at the forefront of advancements in AD detection.

Their dedication to innovation and teamwork drives their mission to make a meaningful impact in the field of Alzheimer's disease. To learn more about ADmit Therapeutics and their groundbreaking technology, visit their website and reach out to their dedicated team